Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMLS1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:48:04 ON 04 SEP 2007

=> File registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:48:18 ON 04 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2007 HIGHEST RN 945955-20-4
DICTIONARY FILE UPDATES: 3 SEP 2007 HIGHEST RN 945955-20-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> E ZD4054

E1	1	ZD366/BI
E2	1	ZD4/BI
E3	0 -->	ZD4054/BI
E4	1	ZD46D08/BI
E5	1	ZD4C/BI
E6	1	ZD4R/BI
E7	3	ZD5/BI
E8	6	ZD52F10/BI
E9	1	ZD54H05/BI
E10	1	ZD582/BI
E11	1	ZD5C/BI
E12	1	ZD5R/BI

=> E ZD4054/CN

E1	1	ZD-B/CN
E2	1	ZD3/CN
E3	0 -->	ZD4054/CN
E4	1	ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3689908)/CN
E5	1	ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3690018)/CN
E6	1	ZDA1/CN
E7	1	ZDA2/CN
E8	1	ZDA3/CN
E9	1	ZDA4/CN
E10	1	ZDBDC/CN
E11	1	ZDC/CN
E12	1	ZDC 2/CN

```
=> E ZD-4054/CN
E1            1      ZD 9720/CN
E2            1      ZD ALLOY/CN
E3            0 --> ZD-4054/CN
E4            1      ZD-A/CN
E5            1      ZD-B/CN
E6            1      ZD3/CN
E7            1      ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3689908)/CN
E8            1      ZD52F10 PROTEIN (HUMAN CLONE IMAGE:3690018)/CN
E9            1      ZDA1/CN
E10           1      ZDA2/CN
E11           1      ZDA3/CN
E12           1      ZDA4/CN

=> E ZD 4054/CN
E1            1      ZD 3705/CN
E2            1      ZD 4/CN
E3            1 --> ZD 4054/CN
E4            1      ZD 4190/CN
E5            1      ZD 4407/CN
E6            1      ZD 4522/CN
E7            1      ZD 4522, CALCIUM SALT/CN
E8            1      ZD 4794/CN
E9            1      ZD 4910/CN
E10           1      ZD 4974/CN
E11           1      ZD 5077/CN
E12           1      ZD 5522/CN

=> S E3
L1            1 "ZD 4054"/CN

=> E ZD 1839
NUMBER OF TERMS TO DISPLAY IS OUT OF RANGE
The total number of terms displayed in a single EXPAND command
must be in the range 5-25.

=> E ZD 1839/CN
E1            1      ZD 182780/CN
E2            1      ZD 1838/CN
E3            1 --> ZD 1839/CN
E4            1      ZD 1989/104/CN
E5            1      ZD 1989/105/CN
E6            1      ZD 2/CN
E7            1      ZD 201/CN
E8            1      ZD 2079/CN
E9            1      ZD 211/CN
E10           1      ZD 2138/CN
E11           1      ZD 2171/CN
E12           1      ZD 2249/CN

=> S E3
L2            1 "ZD 1839"/CN

=> D L1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   186497-07-4  REGISTRY
ED   Entered STN:  27 Feb 1997
CN   3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-
     oxadiazol-2-yl)phenyl]-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-[4-(1,3,4-
     oxadiazol-2-yl)phenyl]- (9CI)
OTHER NAMES:
CN   ZD 4054
```

CN Zibotentan
MF C19 H16 N6 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> D L1 IDE

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 186497-07-4 REGISTRY
ED Entered STN: 27 Feb 1997
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (9CI)
OTHER NAMES:
CN ZD 4054
CN Zibotentan
MF C19 H16 N6 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> D L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 184475-35-2 REGISTRY
ED Entered STN: 26 Dec 1996
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)
OTHER NAMES:
CN (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine
CN 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
CN Gefitinib
CN Iressa
CN ZD 1839
MF C22 H24 Cl F N4 O3
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1446 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1456 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> File caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 18.90 | 19.11

FILE 'CAPLUS' ENTERED AT 16:52:39 ON 04 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 3 Sep 2007 (20070903/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L1
L3 19 L1

=> S L2
L4 1456 L2

=> S L1 and L2
19 L1
1456 L2
L5 7 L1 AND L2

=> D L5 1-7 IBIB abs

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:748964 CAPLUS
TITLE: Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity
AUTHOR(S): Rosano, Laura; Di Castro, Valeriana; Spinella, Francesca; Tortora, Giampaolo; Nicotra, Maria Rita; Natali, Pier Giorgio; Bagnato, Anna
CORPORATE SOURCE: Molecular Pathology and Immunology Laboratories, Regina Elena Cancer Institute, Institute of Molecular Biology and Pathology, National Research Council, Rome, Endocrinology and Molecular Oncology Department, University of Naples, Federico II, Naples, Italy
SOURCE: Cancer Research (2007), 67(13), 6351-6359

CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ovarian carcinomas overexpress endothelin A receptors (ETAR) and epidermal growth factor (EGF) receptor (EGFR). In these cells, endothelin-1 (ET-1) triggers mitogenic and invasive signaling pathways that are in part mediated by EGFR transactivation. Combined targeting of ETAR, by the specific ETAR antagonist ZD4054, and of EGFR by the EGFR inhibitor gefitinib (IRESSA), may offer improvements in ovarian carcinoma treatment. In HEY and OVCA 433 ovarian carcinoma cells, ET-1 or EGF induced rapid activation of EGFR, p42/44 mitogen-activated protein kinase (MAPK), and AKT. ZD4054 was able to reduce the ET-1-induced EGFR transactivation. Gefitinib significantly inhibited EGF- and ET-1-induced EGFR phosphorylation, but incompletely reduced the ET-1-induced activation of downstream targets. ZD4054 plus gefitinib resulted in a greater inhibition of EGFR, MAPK, and AKT phosphorylation, indicating the critical role of these interconnected signaling proteins. ZD4054 effectively inhibited cell proliferation, invasiveness, and vascular endothelial growth factor (VEGF) secretion. Concomitantly, ZD4054 enhanced apoptosis and E-cadherin promoter activity and expression. In both cell lines, the drug combination resulted in a significant decrease in cell proliferation (65%), invasion (52%), and VEGF production (50%), accompanied by a 2-fold increase in apoptosis. The coadministration of ZD4054 enhanced the efficacy of gefitinib leading to partial (82%) or complete tumor regression on HEY ovarian carcinoma xenografts. Antitumor effects were paralleled by biochem. and immunohistol. evidence of decreased vascularization, Ki-67, matrix metalloproteinase-2 (MMP-2), VEGF, MAPK and EGFR, and enhanced E-cadherin expression. The cross-signaling between the EGFR/ETAR pathways provides a rationale to combine EGFR inhibitors with ETAR antagonists, identifying new effective therapeutic opportunities for ovarian cancer.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:619578 CAPLUS
DOCUMENT NUMBER: 147:46112
TITLE: Treatment of cancer and other diseases
INVENTOR(S): Habib, Nabil
PATENT ASSIGNEE(S): Nabil Habib Lab, Lebanon; Vianova Labs, Inc.
SOURCE: PCT Int. Appl., 86pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064691	A1	20070607	WO 2006-US45665	20061130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-741725P P 20051202
OTHER SOURCE(S): MARPAT 147:46112

AB The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1290072 CAPLUS

DOCUMENT NUMBER: 144:46998

TITLE: The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design

INVENTOR(S): Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247346	A1	20051208	AU 2005-247346	20050509
CA 2569003	A1	20051208	CA 2005-2569003	20050509
EP 1773389	A2	20070418	EP 2005-780060	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

PRIORITY APPLN. INFO.: US 2004-569131P P 20040507
WO 2005-US15981 W 20050509

AB The present invention relates to compds. (e.g., peptidomimetics and non-peptides) that treat, prevent or stabilize cellular proliferative disorders and methods of treating, preventing, or stabilizing such disorders. The invention also provides three-dimensional structures of a BRCT domain-BACH1 phosphopeptide complex.

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409543 CAPLUS

DOCUMENT NUMBER: 142:457053

TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy

INVENTOR(S): Lacasse, Eric; McManus, Daniel

PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.

SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005042558	A1	20050512	WO 2004-CA1902		20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005148535	A1	20050707	US 2004-975974		20041028
CA 2542904	A1	20050512	CA 2004-2542904		20041029
EP 1682565	A1	20060726	EP 2004-789809		20041029
R: DE, FR, GB					
JP 2007510408	T	20070426	JP 2006-537024		20041029
PRIORITY APPLN. INFO.:			US 2003-516192P	P	20031030
			WO 2004-CA1902	W	20041029

AB The invention provides nucleobase oligomers and oligonucleotide duplexes that inhibit expression of an IAP (inhibitor of apoptosis protein), and methods for using them to induce apoptosis in a cell. Specifically, the invention provides nucleic acid sequences for siRNAs and shRNAs that target human XIAP, HIAP-1 or HIAP-2 genes. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compns. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent. RNAi sequences and vectors producing shRNA (short hairpin RNA) were transfected into HeLa cells and evaluated for their effect on XIAP, cIAP-1, or cIAP-2 protein levels. XIAP protein could also be reduced by RNAi clones in transfected breast cancer cell line MDA-MB-231. In addition, cell survival was reduced in XIAP RNAi transfected breast cancer cell line after the transfected cells were treated with TRAIL (tumor necrosis factor-related apoptosis inducing ligand).

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:409357 CAPLUS
DOCUMENT NUMBER: 142:457052
TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005119217	A1	20050602	US 2004-975790		20041028
AU 2004284855	A1	20050512	AU 2004-284855		20041029
CA 2542884	A1	20050512	CA 2004-2542884		20041029
EP 1691842	A1	20060823	EP 2004-789807		20041029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004015779	A	20061226	BR 2004-15779		20041029
CN 1901939	A	20070124	CN 2004-80039601		20041029
JP 2007509861	T	20070419	JP 2006-537023		20041029
IN 2006MN00614	A	20070420	IN 2006-MN614		20060526
NO 2006002420	A	20060731	NO 2006-2420		20060529
PRIORITY APPLN. INFO.:			US 2003-516263P	P	20031030
			WO 2004-CA1900	W	20041029

AB The invention claims the use of an antisense oligomer to human XIAP, IAP-1 or IAP-2 genes and a chemotherapeutic agent, and compns. and kits thereof, for the treatment of proliferative diseases. The invention further claims sequences for nucleobase oligomers that are antisense IAP (inhibitor of apoptosis protein) oligomers. The antisense IAP nucleobase oligomers specifically hybridize with polynucleotides encoding an IAP and reduce the amount of an IAP protein produced in a cell. Thus by reducing the IAP protein, the invention provides methods for inducing cancer cells to undergo apoptosis and for overriding anti-apoptotic signals in cancer cells. As an example of the invention, mice with s.c. H460 human lung carcinoma xenografts were injected intratumorally with XIAP antisense mixed-base 2'-O-Me RNA oligonucleotides (C5 and/or G4) and the drug vinorelbine. At the end of the 24 d treatment period, the mean relative tumor growth was reduced .apprx.70% in treated mice. The inhibition of tumor growth was correlated with down-regulation of human XIAP protein expression and an increased number of dead cells. The mice did not show any signs of cytotoxicity such as body weight loss.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:283298 CAPLUS
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004154316	A1	20040812	US 2003-359834	20030207
CA 2515188	A1	20040826	CA 2004-2515188	20040203
WO 2004072913	A2	20040826	WO 2004-US3021	20040203
WO 2004072913	A3	20041111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1590776	A2	20051102	EP 2004-707767	20040203

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004007281	A	20060131	BR 2004-7281	20040203
CN 1754192	A	20060329	CN 2004-80005053	20040203
AU 2004273910	A1	20050331	AU 2004-273910	20040916
CA 2538570	A1	20050331	CA 2004-2538570	20040916
EP 1670477	A2	20060621	EP 2004-788798	20040916

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004014568	A	20061107	BR 2004-14568	20040916
CN 1878556	A	20061213	CN 2004-80033294	20040916
JP 2007505914	T	20070315	JP 2006-527024	20040916
MX 2005PA08325	A	20060228	MX 2005-PA8325	20050805
MX 2006PA03066	A	20060620	MX 2006-PA3066	20060317
NO 2006001325	A	20060606	NO 2006-1325	20060323

PRIORITY APPLN. INFO.:	US 2003-504310P	P	20030918
	US 2003-359834	A	20030207
	WO 2004-US3021	W	20040203
	WO 2004-US30368	W	20040916

OTHER SOURCE(S): MARPAT 142:349042

AB The invention discloses a method for treating a patient having a cancer or other neoplasm by administering chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amts. sufficient to treat the patient.

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:354796 CAPLUS
DOCUMENT NUMBER:	140:368653
TITLE:	Endothelin receptor antagonist-EGF receptor tyrosine kinase inhibitor combination for the treatment of cancer
INVENTOR(S):	Boyle, Francis Thomas; Curwen, Jon Owen; Gallagher, Neil James; Hancox, Ursula Joy; Hughes, Andrew Mark; Johnstone, Donna; Taylor, Sian Tomiko; Tonge, David William
PATENT ASSIGNEE(S):	Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:	PCT Int. Appl., 24 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035057	A1	20040429	WO 2003-GB4347	20031007

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2501959          A1   20040429    CA 2003-2501959        20031007
    AU 2003269259       A1   20040504    AU 2003-269259         20031007
    AU 2003269259       B2   20070315
    EP 1553950          A1   20050720    EP 2003-751038         20031007
    EP 1553950          B1   20070808
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003015140       A    20050816    BR 2003-15140          20031007
    CN 1703224          A    20051130    CN 2003-80101310       20031007
    JP 2006510605       T    20060330    JP 2004-544431         20031007
    AT 369136           T    20070815    AT 2003-751038         20031007
    NO 2005001658       A    20050506    NO 2005-1658           20050404
    MX 2005PA03808      A    20050608    MX 2005-PA3808         20050408
    ZA 2005002874       A    20060222    ZA 2005-2874           20050408
    US 2006122180       A1   20060608    US 2005-530794         20050408
PRIORITY APPLN. INFO.:                   GB 2002-23854       A  20021012
                                         WO 2003-GB4347      W  20031007
AB   A combination, comprising an endothelin receptor antagonist (e.g. ZD4054),
     or a pharmaceutically acceptable salt thereof, and an EGF receptor
     tyrosine kinase inhibitor (e.g. ZD1839), or a pharmaceutically acceptable
     salt thereof, is described.  The combination of the invention is useful
     for the treatment of cancer, e.g. prostate cancer.
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> File uspat2 uspatfull
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  23.10      42.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -5.46      -5.46

FILE 'USPAT2' ENTERED AT 16:57:08 ON 04 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:57:08 ON 04 SEP 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s L1
L6           11 L1

=> s L2
L7          279 L2

=> S L1 and L2
L8            3 L1 AND L2

=> d L8 1-3 IBIB abs

L8   ANSWER 1 OF 3  USPATFULL on STN
ACCESSION NUMBER:        2006:144662  USPATFULL
TITLE:                   Therapeutic treatment
INVENTOR(S):             Boyle, Francis Thomas, Cheshire, UNITED KINGDOM
```

Curwen, Jon Owen, Cheshire, UNITED KINGDOM
Gallagher, Neil James, Cheshire, UNITED KINGDOM
Hancox, Ursula Joy, Cheshire, UNITED KINGDOM
Hughes, Andrew Mark, Cheshire, UNITED KINGDOM
Johnstone, Donna, Cheshire, UNITED KINGDOM
Taylor, Sian Tomiko, Cheshire, UNITED KINGDOM
Tonge, David William, Cheshire, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006122180	A1	20060608	
APPLICATION INFO.:	US 2003-530794	A1	20031007	(10)
	WO 2003-GB4347		20031007	
			20050408	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-23854	20021012

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ASTRAZENECA R&D BOSTON, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451-1215, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof is described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2005:171786 USPATFULL
TITLE: IAP nucleobase oligomers and oligomeric complexes and uses thereof
INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005148535	A1	20050707	
APPLICATION INFO.:	US 2004-975974	A1	20041028	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516192P	20031030 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 3022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2005:138567 USPATFULL
TITLE: Methods and reagents for the treatment of proliferative diseases
INVENTOR(S): LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
Durkin, Jon P., Montreal, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005119217	A1	20050602
APPLICATION INFO.:	US 2004-975790	A1	20041028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-516263P	20031030 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 5896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods, compositions, and kits for treating a patient having a proliferative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> FILE MEDLINE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.33	64.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.46

FILE 'MEDLINE' ENTERED AT 17:03:29 ON 04 SEP 2007

FILE LAST UPDATED: 1 Sep 2007 (20070901/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1
L9 0 L1

=> S L2
L10 1263 L2

=> File caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.21	65.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.46

FILE 'CAPLUS' ENTERED AT 17:05:32 ON 04 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 3 Sep 2007 (20070903/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> D L5 1 full
'FULL' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms

HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):all

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:748964 CAPLUS
ED Entered STN: 11 Jul 2007
TI Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity
AU Rosano, Laura; Di Castro, Valeriana; Spinella, Francesca; Tortora, Giampaolo; Nicotra, Maria Rita; Natali, Pier Giorgio; Bagnato, Anna
CS Molecular Pathology and Immunology Laboratories, Regina Elena Cancer Institute, Institute of Molecular Biology and Pathology, National Research Council, Rome, Endocrinology and Molecular Oncology Department, University of Naples, Federico II, Naples, Italy
SO Cancer Research (2007), 67(13), 6351-6359
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1, 2
AB Ovarian carcinomas overexpress endothelin A receptors (ETAR) and epidermal growth factor (EGF) receptor (EGFR). In these cells, endothelin-1 (ET-1) triggers mitogenic and invasive signaling pathways that are in part mediated by EGFR transactivation. Combined targeting of ETAR, by the specific ETAR antagonist ZD4054, and of EGFR by the EGFR inhibitor gefitinib (IRESSA), may offer improvements in ovarian carcinoma treatment. In HEY and OVCA 433 ovarian carcinoma cells, ET-1 or EGF induced rapid activation of EGFR, p42/44 mitogen-activated protein kinase (MAPK), and AKT. ZD4054 was able to reduce the ET-1-induced EGFR transactivation. Gefitinib significantly inhibited EGF- and ET-1-induced EGFR phosphorylation, but incompletely reduced the ET-1-induced activation of downstream targets. ZD4054 plus gefitinib resulted in a greater inhibition of EGFR, MAPK, and AKT phosphorylation, indicating the critical role of these interconnected signaling proteins. ZD4054 effectively inhibited cell proliferation, invasiveness, and vascular endothelial growth factor (VEGF) secretion. Concomitantly, ZD4054 enhanced apoptosis and E-cadherin promoter activity and expression. In both cell lines, the drug combination resulted in a significant decrease in cell proliferation (65%), invasion (52%), and VEGF production (50%), accompanied by a 2-fold increase in apoptosis. The coadministration of ZD4054 enhanced the efficacy of gefitinib leading to partial (82%) or complete tumor regression on HEY ovarian carcinoma xenografts. Antitumor effects were paralleled by biochem. and immunohistol. evidence of decreased

vascularization, Ki-67, matrix metalloproteinase-2 (MMP-2), VEGF, MAPK and EGFR, and enhanced E-cadherin expression. The cross-signaling between the EGFR/ETAR pathways provides a rationale to combine EGFR inhibitors with ETAR antagonists, identifying new effective therapeutic opportunities for ovarian cancer.

ST EAR EGFR signaling ZD4054 gefitinib ovary cancer antitumor synergist

IT Cadherins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(1; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Ovary, neoplasm
(carcinoma; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Antitumor agents
Apoptosis
Cell proliferation
Combination chemotherapy
Drug targets
Human
Signal transduction, biological
(combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Endothelin ETA receptors
Epidermal growth factor receptors
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Cell proliferation
(inhibition; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Carcinoma, neoplasm
(ovarian; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Phosphorylation, biological
(protein; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT Drug interactions
(synergistic; combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT 79079-06-4, Epidermal growth factor receptor tyrosine kinase 123626-67-5, Endothelin 1 127464-60-2, Vascular endothelial growth factor 137632-07-6D, p44 mitogen-activated protein kinase, phosphorylation 137632-08-7D, p42 mitogen-activated protein kinase, phosphorylation 146480-35-5, matrix metalloproteinase-2 148640-14-6D, Akt kinase, phosphorylation
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

IT 184475-35-2, Gefitinib 186497-07-4, ZD4054
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined targeting of ETAR/EGFR-mediated signaling pathways in ovarian cancer by ZD4054 and gefitinib-induced increased antitumor activity)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bagnato, A; Cancer Res 1997, V57, P1306 CAPLUS

(2) Bagnato, A; Cancer Res 1999, V59, P720 CAPLUS
(3) Bagnato, A; Clin Cancer Res 1995, V1, P1059 CAPLUS
(4) Bagnato, A; Endocr Relat Cancer 2005, V12, P761 CAPLUS
(5) Bartlett, J; Br J Cancer 1996, V73, P301 CAPLUS
(6) Bianco, R; Endocr Relat Cancer 2005, V12, P159
(7) Bignotti, E; Am J Obstet Gynecol 2007, V196, P245.e1
(8) Ciardiello, F; Clin Cancer Res 2004, V10, P784 CAPLUS
(9) Del Bufalo, D; Mol Pharmacol 2002, V61, P524 CAPLUS
(10) Donninger, H; Oncogene 2004, V23, P8065 CAPLUS
(11) Grunwald, V; Breast Cancer Res Treat 1996, V38, P67
(12) Jazaeri, A; Clin Cancer Res 2005, V11, P6300 CAPLUS
(13) Jemal, A; CA Cancer J Clin 2006, V56, P106
(14) Lister-Sharp, D; Health Technol Assess 2000, V4, P1 MEDLINE
(15) Mavroudis, D; Proc Am Soc Clin Oncol 2004, V22, P5020
(16) Morris, C; Br J Cancer 2005, V92, P2148 CAPLUS
(17) Naora, M; Nat Rev Cancer 2005, V5, P355
(18) Nelson, J; Nat Rev Cancer 2003, V3, P110 CAPLUS
(19) O'Reilly, M; Clin Cancer Res 2002, V8, P3309
(20) Pautier, P; Proc Am Soc Clin Oncol 2004, V22, P5015
(21) Ranson, M; J Clin Oncol 2002, V20, P2240 CAPLUS
(22) Ranson, M; Oncologist 2002, V7, P16 CAPLUS
(23) Rosano, L; Cancer Res 2001, V61, P8340 CAPLUS
(24) Rosano, L; Cancer Res 2003, V63, P2447 CAPLUS
(25) Rosano, L; Cancer Res 2005, V65, P11649 CAPLUS
(26) Rosano, L; Exp Biol Med (Maywood) 2006, V231, P1132 CAPLUS
(27) Rosano, L; Mol Cancer Ther 2006, V5, P833 CAPLUS
(28) Rosano, L; Mol Cancer Ther In press 2007
(29) Rubanyi, G; Pharmacol Rev 1994, V4, P325
(30) Salani, D; Am J Pathol 2000, V157, P1537 CAPLUS
(31) Scambia, G; Br J Cancer 1995, V72, P361 CAPLUS
(32) Schilder, R; Clin Cancer Res 2005, V11, P5539 CAPLUS
(33) Spinella, F; Clin Cancer Res 2004, V10, P4670 CAPLUS
(34) Spinella, F; J Biol Chem 2003, V278, P41294 CAPLUS
(35) Spinella, F; J Biol Chem 2004, V279, P46700 CAPLUS
(36) Thomson, S; Cancer Res 2005, V65, P9455 CAPLUS
(37) Vacca, F; Cancer Res 2000, V60, P5310 CAPLUS
(38) Wakeling, A; Cancer Res 2002, V62, P5749 CAPLUS
(39) Weidner, N; N Engl J Med 1991, V324, P1 MEDLINE
(40) Witta, S; Cancer Res 2006, V66, P944 CAPLUS
(41) Yauch, R; Clin Cancer Res 2005, V11, P8686 CAPLUS

=> D L5 2 all

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:619578 CAPLUS
DN 147:46112
ED Entered STN: 08 Jun 2007
TI Treatment of cancer and other diseases
IN Habib, Nabil
PA Nabil Habib Lab, Lebanon; Vianova Labs, Inc.
SO PCT Int. Appl., 86pp.
CODEN: PIXXD2
DT Patent
LA English
CC 1-6 (Pharmacology)
Section cross-reference(s): 32
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007064691	A1	20070607	WO 2006-US45665	20061130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRAI US 2005-741725P P 20051202
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2007064691	IPCI	A61K0031-575 [I,A]

OS MARPAT 147:46112

AB The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other diseases including hypercholesterolemia, autoimmune diseases, viral diseases (e.g., hepatitis B, hepatitis C, or HIV), and diabetes.

ST cancer disease treatment ethylcholestane triol combination therapy

IT 5-HT agonists
(5-HT2C; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AGE (advanced glycosylation end product), inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Purinoceptor agonists
(A1; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Purinoceptor agonists
(A2; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Lymphoma
(B-cell diffuse, large cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Cholecystokinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CCKA, agonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Infection
(Chagas' disease; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Inflammation
(Crohn's disease; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Intestine, disease
(Crohn's; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Dopamine agonists
(D1; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Dopamine agonists
(D2; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Bone, neoplasm
(Ewing's sarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Sarcoma
(Ewing's; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Arthritis
(Felty's syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Kidney, disease
(Goodpasture's syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Nervous system, disease
(Guillain-Barre syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Purpura (disease)
(Henoch-Schoenlein's; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Cytokines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IRX-2; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Kidney, disease
(IgA nephropathy; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Sarcoma
(Kaposi's; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood vessel, disease
(Kawasaki; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Lp(a), antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Disease, animal
(Muckle-Wells syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood vessel, disease
(Raynaud's phenomenon; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Arthritis
(Reiter's syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, neoplasm
(Sezary syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V1, antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Vasopressin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V2, antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Granulomatous disease
(Wegener's granulomatosis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Kidney, neoplasm
(Wilms'; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Nerve, neoplasm
(acoustic neuroma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Acute myeloid leukemia

(acute erythroblastic leukemia; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Carcinoma
Ovary, neoplasm
Vaccines
(adenocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Neuropeptide Y receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists and antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Atrial natriuretic peptide receptors
Corticotropin releasing factor receptors
Glucagon-like peptide-1 receptors
Nerve growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Respiratory system, disease
(allergic bronchopulmonary aspergillosis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Allergy
(allergic contact dermatitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Dermatitis
(allergic contact; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Allergy
Inflammation
Nerve, disease
(allergic neuritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Lung, disease
(alveolar proteinosis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amylin, agonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Edema
(angioneurotic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Inflammation
Spinal column, disease
(ankylosing spondylitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Granuloma
(annulare; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Cannabinoid receptors
Growth hormone receptors
Melanin-concentrating hormone receptors
Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Anemia (disease)
(aplastic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apolipoprotein A-I, agonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Alopecia
(areata; treatment of cancer and other diseases using ethylcholestane

triol and combination with other agents)
IT Artery, disease
Inflammation
(arteritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Mycosis
(aspergillosis, Allergic bronchopulmonary; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Neuroglia, neoplasm
(astrocytoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Nervous system, disease
(ataxia telangiectasia; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Dermatitis
(atopic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Autoimmune disease
Inflammation
Kidney, disease
(autoimmune glomerulonephritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Anemia (disease)
Autoimmune disease
(autoimmune hemolytic anemia; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Autoimmune disease
(autoimmune myasthenia gravis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Autoimmune disease
Inflammation
Ovary, disease
(autoimmune oophoritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Endocrine system, disease
(autoimmune polyendocrine failure; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Myasthenia gravis
(autoimmune; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, neoplasm
(basal cell carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(basal cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Biliary tract, neoplasm
(bile duct, carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(binding agents and transport inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(bladder; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(bronchial; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Drug delivery systems
(buccal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Mycosis
(candidiasis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Bladder, neoplasm
Bronchi, neoplasm
Lung, neoplasm
Sebaceous gland
Sweat gland
(carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Sarcoma
(cartilage chondrosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Uterus, neoplasm
(cervix, carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(cervix; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(choledochal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholesterol ester-exchanging, antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Cartilage, neoplasm
(chondrosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Neoplasm
(chordoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
Chorion, neoplasm
(choriocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Intestine, neoplasm
(colon, carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(colon; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Intestine, neoplasm
(colorectal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Brain, neoplasm
(craniopharyngioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Cryoglobulins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(cryoglobulinemia; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Ovary, neoplasm
(cystadenocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(depsipeptides; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lupus erythematosus
(discoid; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Reticuloendothelial system
(disease, histiocytosis, X; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Eosinophil
(disease, hypereosinophilic syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine transporter, inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Eye, disease
(dry eye syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(embryonal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Brain, neoplasm
(ependymoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood vessel, disease
Skin, disease
(erythema nodosum; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Amyloidosis
(familial Mediterranean fever; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Fever and Hyperthermia
(familial Mediterranean; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Sarcoma
(fibrosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lung, disease
(fibrosis, cryptogenic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Radicals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Mycosis
(fungoides; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Inflammation
Kidney, disease
(glomerulonephritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Kidney, disease
(glomerulus, membranous; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Transplant and Transplantation
(graft-vs.-host reaction; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lung, disease
Myositis
(granulomatous; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood vessel, neoplasm

(hemangioblastoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood vessel, neoplasm
Sarcoma
(hemangiosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(hepatocellular; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Liver, neoplasm
(hepatoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Edema
(hereditary angioneurotic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Disease, animal
(histiocytosis, X; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Blood, disease
(hypereosinophilic syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Allergy
(hypersensitivity; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Purpura (disease)
(idiopathic thrombocytopenic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Agranulocytosis
(immune-mediated; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Hepatitis B virus
Hepatitis C virus
Human immunodeficiency virus
(infection; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(inhalants; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lipid peroxidation
(inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(injections, i.a.; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(injections, i.m.; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(injections, i.v.; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(injections, s.c.; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(intrathecal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(intratumoral; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Rheumatoid arthritis
(juvenile; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Eye, disease
Inflammation
(keratitis; treatment of cancer and other diseases using

ethylcholestane triol and combination with other agents)
IT Lung, neoplasm
(large-cell carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Myoma
Sarcoma
(leiomyosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Adipose tissue, neoplasm
Sarcoma
(liposarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Sarcoma
(lymphangiosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Erythema
(marginatum; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Thyroid gland, neoplasm
(medullary carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Brain, neoplasm
(medulloblastoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Vaccines
(melanoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Nervous system, neoplasm
(meningioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Mesothelium, neoplasm
(mesothelioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microsomal, inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Connective tissue, disease
(mixed connective tissue disease; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Erythema
(multiforme; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, neoplasm
(mycosis fungoides; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Astrocyte
(neoplasm, astrocytoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Notochord
(neoplasm, chordoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Meninges
(neoplasm, meningioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Oligodendrocyte
(neoplasm, oligodendroglioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Synovial membrane, disease
(neoplasm, sarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Schwann cell
(neoplasm, schwannoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Kidney, disease
(nephrotic syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Nerve, neoplasm
(neuroblastoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Hemolysis
(newborn; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lymphoma
(non-Hodgkin's; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Neuroglia, neoplasm
(oligodendroglioma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(oral; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Inflammation
Testis, disease
(orchitis, autoimmune; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Bone, neoplasm
Sarcoma
(osteosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(ovarian adenocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(ovarian cystadenocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Vaccines
(p21 ras protein; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Ras proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p21ras, vaccines; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(papillary adenocarcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(papillary; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, disease
(pemphigoid; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, disease
(pemphigus foliaceus; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, disease
(pemphigus vulgaris; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Skin, disease
(pemphigus; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Artery, disease
Inflammation
(periarteritis nodosa; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Albumins, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphorus 32 and; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Brain, neoplasm
(pinealoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Inflammation
Lung, disease
(pneumonitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Muscle, disease
(polymyalgia rheumatica; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Myositis
(polymyositis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Nerve, disease
(polyneuropathy, Portuguese familial; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Disease, animal
(post-myocardial infarction syndrome; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Biliary tract, disease
(primary biliary cirrhosis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Arthritis
(psoriatic arthritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Carcinoma
(pulmonary large-cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Carcinoma
(pulmonary small-cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Fibrosis
(pulmonary, cryptogenic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Carcinoma
Granulomatous disease
(pulmonary; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Drug delivery systems
(rectal; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Kidney, neoplasm
(renal cell carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Carcinoma
(renal cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Eye, neoplasm
(retinoblastoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Sarcoma
(rhabdomyosarcoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Nervous system, neoplasm
(schwannoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Eye, disease
Inflammation
(scleritis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Connective tissue, disease

(scleroderma, CREST syndrome variant; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Connective tissue, disease
(scleroderma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Biliary tract, disease
Inflammation
(sclerosing cholangitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Testis, neoplasm
(seminoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lung, neoplasm
(small-cell carcinoma; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(squamous cell; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Bone formation
(stimulants; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Encephalitis
(subacute sclerosing panencephalitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Sarcoma
(synovial membrane; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Lupus erythematosus
Mastocytosis
(systemic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Thrombosis
(thromboangiitis obliterans; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Carcinoma
(thyroid medullary; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT Drug delivery systems
(topical; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)
IT AIDS (disease)
Acute monocytic leukemia
Acute myeloid leukemia
Acute promyelocytic leukemia
Addison's disease
Amyloidosis
Anaphylaxis
Angiogenesis inhibitors
Angiotensin receptor antagonists
Angiotensin-converting enzyme inhibitors
Anti-AIDS agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Anticholesteremic agents
Antidiabetic agents
Antioxidants
Antirheumatic agents
Antitumor agents
Antiviral agents
Asthma

Autoimmune disease
Behcet's syndrome
Calcium channel blockers
Calcium channel openers
Carcinoma
Celiac disease
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Combination chemotherapy
Cyclooxygenase 2 inhibitors
Cytotoxic agents
DiGeorge syndrome
Diabetes mellitus
Diuretics
Endothelin receptor antagonists
Glutamate antagonists
Graves' disease
HMG-CoA reductase inhibitors
Hemochromatosis
Hepatitis
Hodgkin's disease
Human
Hypercholesterolemia
Immunomodulators
Leprosy
Leukemia
Lyme disease
Mammary gland, neoplasm
Melanoma
Myocarditis
Neoplasm
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Ovary, neoplasm
Oxidizing agents
Pancreas, neoplasm
Paroxysmal nocturnal hemoglobinuria
Peroxisome proliferators
Platelet aggregation inhibitors
Polycythemia vera
Preeclampsia
Prostate gland, neoplasm
Psoriasis
Rheumatic fever
Sarcoidosis
Selective estrogen receptor modulators
Serotonin-noradrenaline reuptake inhibitors
Sjogren syndrome
Testis, neoplasm
Thromboxane receptor antagonists
Transplant rejection
Urticaria
Uterus, neoplasm
Uveitis
Vitiligo
Wiskott-Aldrich syndrome
α1-Adrenoceptor antagonists
α2-Adrenoceptor agonists
β-Adrenoceptor antagonists
β3-Adrenoceptor agonists
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of cancer and other diseases using ethylcholestane triol and

combination with other agents)

IT Estrogens
Sulfonylureas
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Vaccines
(tumor; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Cytotoxic agents
(tyrphostins; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Inflammation
Intestine, disease
(ulcerative colitis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Connective tissue, disease
(undifferentiated; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Alopecia
(universalis; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Antitumor agents
(vaccines; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Blood vessel, disease
Inflammation
(vasculitis, necrotic; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Infection
(viral; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 209973-83-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BLP 25; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 606967-38-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MX 6; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 824975-76-0, P 54 (pharmaceutical)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(P 54; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(absorption inhibitors and antagonists; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 14596-37-3, 32P, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(albumin solns. containing; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 9000-83-3, ATPase 9001-42-7, α-Glucosidase 9001-62-1, Lipase 9001-92-7, Endopeptidase 9012-90-2, DNA polymerase 9015-82-1 9028-35-7 9029-62-3, Squalene epoxidase 9068-52-4, Phosphodiesterase V 9077-14-9, Squalene synthase 54249-88-6, Dipeptidyl peptidase IV 61276-89-9, Thromboxane synthase 80449-01-0, DNA topoisomerase 82707-54-8, Vasopeptidase 125978-95-2, Nitric oxide synthase 133876-97-8, Phospholipase A2 143375-65-9, Cdc2 kinase 182372-13-0, Rho kinase 329900-75-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 83-46-5, β-Sitosterol 11040-28-1, α-Sitosterol
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 372092-80-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein kinase, inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 79747-53-8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein tyrosine phosphatase, inhibitors; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sensitizers and treatment with; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 13444-71-8, Periodic acid (HIO4)
RL: RGT (Reagent); RACT (Reactant or reagent)
(sitosterol oxidation by; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 9054-75-5, Guanylate cyclase 9055-65-6, Prostaglandin synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stimulants; treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 20816-12-0, Osmium tetroxide
RL: CAT (Catalyst use); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 73544-41-9P, 24-Ethylcholestane 3,5,6 triol 133697-68-4P 939960-57-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and combination with other agents)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-91-9, Floxuridine 51-45-6, Histamine, biological studies 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 54-42-2, Idoxuridine 55-98-1, Busulfan 56-03-1D, Biguanide, analogs 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-05-2, Methotrexate 64-86-8, Colchicine 65-46-3D, Cytidine, ethynyl derivs. 70-00-8, Trifluridine 76-43-7, Fluoxymesterone 83-43-2, Methylprednisolone 84-17-3, Dienestrol 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 145-63-1, Suramin 147-94-4, Cytarabine 154-42-7, 6-Thioguanine 154-93-8, Carmustine 302-79-4, trans-Retinoic acid 305-03-3, Chlorambucil 320-67-2, Azacytidine 331-39-5, Caffeic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 469-83-0, Cafestol 481-74-3, Chrysophanic acid 518-82-1, Emodin 520-85-4, Medroxyprogesterone 536-59-4, Perillyl alcohol 548-04-9, Hypericin

566-48-3, Formestane 569-57-3, Chlorotrianisene 616-91-1, N-Acetylcysteine 630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine 646-08-2, β-Alethine 671-16-9, Procarbazine 768-94-5, Amantadine 801-52-5, Porfiromycin 865-21-4, Vinblastine 1362-42-1, Absinthin 2353-33-5, Decitabine 3056-17-5, Stavudine 3432-99-3, CoFactor 3562-63-8, Megestrol 3778-73-2, Ifosfamide 4105-38-8 4291-63-8, 2-Chlorodeoxyadenosine 4342-03-4, Dacarbazine 4428-95-9, Foscarnet 4707-32-8, β-Lapachone 4891-15-0, Estramustine phosphate 5300-03-8, Alitretinoin 5536-17-4, Vidarabine 5825-87-6, 3CPA 6894-43-5, Kahweol 7481-89-2, Zalcitabine 9004-10-8D, Insulin, analogs, biological studies 10212-20-1 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13392-28-4, Rimantadine 13909-09-6, Semustine 15663-27-1, Cisplatin 15866-90-7, CMT-3 16208-51-8, BNP-7787 18378-89-7, Plicamycin 18883-66-4, Streptozocin 19685-09-7, Hydroxycamptothecin 19916-73-5, O6-Benzylguanine 20281-00-9D, Cesium oxide, analogs 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 24584-09-6, Dexrazoxane 26833-87-4, Ceflatonin 27314-97-2, Tirapazamine 29767-20-2, Teniposide 30516-87-1, Zidovudine 30811-80-4, Polycytidylic acid 33069-62-4, Paclitaxel 33419-42-0, Etoposide 36791-04-5, Ribavirin 38390-45-3, Anhydrovinblastine 39809-25-1, Penciclovir 41575-94-4, Carboplatin 41941-56-4, Tocladesine 51264-14-3, Amsacrine 51543-40-9, R-Flurbiprofen 52128-35-5, Trimetrexate 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Deoxycoformycin 54083-22-6, Rubidazone 56124-62-0, Valrubicin 56420-45-2, Epirubicin 56509-01-4, Immunol 58880-19-6, Trichostatin A 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59277-89-3, Acyclovir 59973-80-7, Exisulind 60084-10-8, Tiazofurin 61825-94-3, Oxaliplatin 62816-98-2, Tetraplatin 62928-11-4, Iproplatin 63612-50-0, Nilutamide 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 65647-66-7, Radicinol 65807-02-5, Goserelin 69408-81-7, Amonafide 69655-05-6, Didanosine 70052-12-9, Eflornithine 71486-22-1, Vinorelbine 72496-41-4, Therarubicin 74790-08-2, Spiroplatin 75037-46-6, Gelonin 75567-37-2, PEP-005 75706-12-6, Leflunomide 81267-65-4, Phenoxodiol 82410-32-0, Ganciclovir 83150-76-9, Octreotide 83314-01-6, Bryostatin-1 84692-91-1, Arglabin 85622-93-1, Temozolomide 86639-52-3, 7-Ethyl-10-hydroxycamptothecin 88303-60-0, Losoxantrone 88859-04-5, Mafosfamide 89778-26-7, Toremifene 90357-06-5, Bicalutamide 90996-54-6, Rhizoxin 91421-42-0, Rubitecan 91441-23-5, Oxantrazole 93908-02-2D, Rebeccamycin, analogs 95058-81-4, Gemcitabine 96301-34-7, Atamestane 96352-57-7, Glucagon-like peptide 97068-30-9, Elsamitrucin 98774-23-3, Tesmilifene 104227-87-4, Famciclovir 107868-30-4, Exemestane 108560-70-9, Gallium maltolate 110230-98-3, Talaporfin 110417-88-4, Dolastatin 10 111358-88-4, CEP-701 112522-64-2, Tacedinaline 112809-51-5, Letrozole 112887-68-0, Tomudex 113852-37-2, Cidofovir 114560-48-4, Apaziquone 114899-77-3, Trabectedin 117048-59-6, Combretastatin A4 119804-96-5, DMDC 120511-73-1, Anastrazole 120685-11-2, Midostaurin 122110-53-6, Pivaloyloxymethyl butyrate 122332-18-7, Mivobulin 123318-82-1, Clofarabine 123948-87-8, Topotecan 124832-26-4, Valacyclovir 125313-92-0, Ro-31-7453 126411-13-0, Apomine 127779-20-8, Saquinavir 129580-63-8, Satraplatin 129618-40-2, Nevirapine 131179-95-8, Efaproxiral 132173-07-0, SR-31747 132682-98-5, Glufosfamide 134404-52-7, Seocalcitol 134678-17-4, Lamivudine 135558-11-1, Lobaplatin 136381-85-6, SR-27897 136817-59-9, Delavirdine 137219-37-5, Aplidine 137281-23-3, Pemetrexed 140917-67-5, Azonafide 141430-65-1, E7010 141732-76-5, Exendin 4 141977-79-9, SM-11355 142340-99-6, Adefovir dipivoxil 143621-35-6, Triapine 144510-96-3, Pixantrone 146426-40-6, Alvocidib 147149-76-6, Nolatrexed 148717-90-2, Squalamine 148869-05-0, YM-511 149204-42-2, Kahalalide F 149606-27-9, Auristatin PE 149647-78-9, SAHA 149682-77-9, PT-100 149838-23-3, Doranidazole 150091-68-2, Quinamed 150378-17-9, Indinavir 152044-54-7, Epothilone B 152459-95-5, Imatinib 153537-73-6, ZD-9331 154039-60-8, Marimastat 154361-50-9, Capecitabine 155213-67-5, Ritonavir 156090-18-5, BBR-3576 156177-59-2, CEP-751 157078-48-3,

Isohomohalichondrin-B 158440-71-2, Irofulven 158681-49-3, MS-209
159776-69-9, Cemadotin 159989-64-7, Nelfinavir 160237-25-2, BMS 184476
162635-04-3, CCI-779 162652-95-1, Vinflunine 165668-41-7, Indisulam
167465-36-3, Zosuquidar trihydrochloride 169317-77-5, MEN-10755
169869-90-3, Exatecan mesylate 172481-83-3, BMS 188797 172903-00-3,
BBR-3464 173937-91-2, Atrasentan 174254-13-8, Biricodar dicitrate
174402-32-5, J-107088 174634-09-4, TAS-103 174722-31-7, Rituximab
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and
combination with other agents)
IT 178600-20-9, LGD-1550 180064-38-4, Minodronic acid 180288-69-1,
Trastuzumab 181630-15-9, ZD-0473 182133-25-1, Arzoxifene
183133-96-2, TXD 258 183319-69-9, OSI-774 183321-74-6, Erlotinib
184475-35-2, Gefitinib 185077-23-0, PI 88 186256-67-7,
Cryptophycin 52 186348-23-2, IDN 5109 186497-07-4, ZD-4054
187724-61-4, PKI166 188968-51-6, Cilengitide 191732-72-6, Revimid
192185-72-1, Tipifarnib 192573-38-9, RPR 109881A 193275-84-2,
Lonafarnib 195533-53-0, T 138067 195612-80-7, Galarubicin
196488-72-9, Ranpirnase 199796-52-6, Taxoprexin 200484-11-3, CHS-828
203258-60-0, Brostallicin 203923-89-1, BNP-1350 204005-46-9, SU5416
204205-90-3, D 24851 204318-14-9, Edotreotide 205923-56-4, C225
206873-63-4, Tariquidar 207862-44-0, KW-2170 209783-80-2, MS-275
212141-54-3, Vatalanib 212142-18-2, PTK787 213819-48-8, CKD-602
216586-46-8, Virulizin 219923-05-4, ZD 6126 219989-84-1, BMS 247550
220578-59-6 220997-97-7, Diflomotecan 227619-96-7, CP-461
232925-18-7, Thymectacin 246252-04-0, Lutetium texaphyrin 246252-06-2,
Motexafin gadolinium 250693-48-2, G 17DT 252916-29-3, SU6668
257933-82-7, EKB-569 257938-36-6, ZD4190 263351-82-2, PG-TXL
267243-28-7, Canertinib 274679-00-4 284461-73-0, BAY-43-9006
284490-13-7, BCX-1777 289499-45-2, CI-1033 292618-32-7, Gimatecan
305838-77-1, Neovastat 337308-14-2, MDX-H 210 339151-96-1, MDX 447
339177-26-3, ABX-EGF 339186-68-4, EMD 72000 342005-82-7, YM-598
343346-07-6, A 105972 373647-71-3, A 204197 380610-27-5, Pertuzumab
387867-13-2, MLN518 400010-39-1, SB 408075 437755-78-7, GW 2016
439943-59-6, TLK-286 443913-73-3, ZD6474 446022-33-9, AG-2037
478011-77-7, RH 3 492448-75-6, Oncophage 531508-98-2, GCS 100
543726-73-4, IMC 1C11 623174-20-9, LU 223651 634599-18-1, WX-UK1
646067-94-9, EKB 509 665026-43-7, CV 247 674289-64-6, AP 5280
848084-84-4, PCK-3145 848866-30-8, GPX 100 848866-33-1, T 900607
848866-35-3, ER 86526 848866-36-4, AZ 10992 848866-48-8, CA 4
(pharmaceutical) 848871-07-8, CBT 1 (inhibitor) 848871-42-1, CDC 394
848872-94-6, P 04 848873-95-0, Theralux 848873-96-1, PBI 1402
848873-97-2, SRL 172 848873-98-3, CDA II 848873-99-4, SDX 101
848874-01-1, SN 4071 848874-02-2, Urocidin 849146-37-8, CTP 37
849146-40-3, Synchrovax 849146-41-4, Pentrix 849146-42-5, ISF 154
849148-55-6, Norelin 849148-82-9, TransMID 107 849148-97-6, MGV
849149-00-4, GMK 851713-35-4, 131I-TM 601
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(treatment of cancer and other diseases using ethylcholestane triol and
combination with other agents)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bouic; EP 0509656 A1 1992 CAPLUS
(2) Eyssen; US 3640848 1972

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.04	76.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-7.02

STN INTERNATIONAL LOGOFF AT 17:11:42 ON 04 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMLS1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation